Elite Pharmaceuticals Inc (ELTP)

[namtae]

Contemplating the buyout scenario presented, there are questions that beg some serious answers

When a companies share price gets depressed, and/or they have little to no money to continue R and D, but do have something valuable to offer, that is when the suitors come knocking.

Now, Ive seen guesses which may have been yours suggesting a buyout of 50 cents/sh. That would equate to an appx $500,000,000 valuation

Just what exactly does Elite possess that any BP would consider such a purchase price?

1. Sequest is in deep trouble. If an approval is even possible, its likely far down the road rendering it obsolete, as in too late to get in the game for a number of reasons. The licensing agreement itself speaks volumes as has the handling of the mysterious data!!

2. A generics business ramping but still only generating $8m in annual sales

3. A pipeline requiring millions to develop and an assessment by whom indicating its potential commercialization value?

In addition, rarely has there been talk of patents. There is nothing more important to a bio company than the strength of its patents because even if theres a sniff from BP, they will walk off into the sunset if there are holes in the patents. Frankly, for little dink companies that miraculously actually develop a drug with huge commercial potential, the patents they hold are usually weak because it takes big $$ and the right patent attorneys to do it right, if its doable. Other than pasting info from the filings, what patents assessment was made that youre privy to?